
Angela M Minassian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1356933/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	13.7	2,080
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
4	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
5	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
6	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	13.7	519
7	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	30.7	473
8	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
9	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
10	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	4.7	190
11	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, The, 2022, 22, 1131-1141.	9.1	99
12	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 167-179.	10.7	89
13	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	12.4	80
14	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med, 2021, 2, 701-719.e19.	4.4	73
15	Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody. Nature Microbiology, 2019, 4, 1497-1507.	13.3	48
16	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial Journal of Infection, 2022, 84, 795-813.	3.3	43
17	Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection. Frontiers in Immunology, 2019, 10, 2983.	4.8	24
18	Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum. ELife, 2021, 10, .	6.0	22

#	Article	IF	CITATIONS
19	Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly. JCI Insight, 2021, 6, .	5.0	22